Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Izanne Roos

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Therapeutic Advances in Neurological Disorders|December 30, 2025
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase RegistryEnrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2Jessica Shipley, James Beharry, Wei Yeh, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1Jessica Shipley, James Beharry, Wei Yeh, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Nature Communications|December 3, 2024
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 yearsMichelle A Neller, George R Ambalathingal, Nada Hamad, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Neurological Disorders|December 30, 2025
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase RegistryEnrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2Jessica Shipley, James Beharry, Wei Yeh, et al.
The Medical Journal of Australia|February 9, 2025
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1Jessica Shipley, James Beharry, Wei Yeh, et al.
Brain : a Journal of Neurology|August 4, 2025
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Nature Communications|December 3, 2024
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 yearsMichelle A Neller, George R Ambalathingal, Nada Hamad, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2023
Comparative effectiveness in multiple sclerosis: A methodological comparisonIzanne Roos, Ibrahima Diouf, Sifat Sharmin, et al.
Pageof 8